A Spiraling Case of Persistent Dysphagia. Diffuse Esophageal Spasm. Patel DA, Vaezi MF (2015) Gastroenterology 149: 298-9 Molecular assembly of botulinum neurotoxin progenitor complexes. Benefield DA, Dessain SK, Shine N, Ohi MD, Lacy DB (2013) Proc Natl Acad Sci U S A 110: 5630-5 Reply to Planche et al. Rao K, Young VB, Aronoff DM (2015) Clin Infect Dis 61: 1211-2 Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality. Rao K, Micic D, Natarajan M, Winters S, Kiel MJ, Walk ST, Santhosh K, Mogle JA, Galecki AT, LeBar W, Higgins PD, Young VB, Aronoff DM (2015) Clin Infect Dis 61: 233-41 A regulated interaction of syntaxin 1A with the antidepressant-sensitive norepinephrine transporter establishes catecholamine clearance capacity. Sung U, Apparsundaram S, Galli A, Kahlig KM, Savchenko V, Schroeter S, Quick MW, Blakely RD (2003) J Neurosci 23: 1697-709 Botulinum toxin in nonachalasia motility disorders: a welcomed therapy in an area with limited therapeutic options. Vaezi MF (2013) Clin Gastroenterol Hepatol 11: 1122-4 Studies of the mechanistic details of the pH-dependent association of botulinum neurotoxin with membranes. Mushrush DJ, Koteiche HA, Sammons MA, Link AJ, McHaourab HS, Lacy DB (2011) J Biol Chem 286: 27011-8 Gβγ inhibits exocytosis via interaction with critical residues on soluble N-ethylmaleimide-sensitive factor attachment protein-25. Wells CA, Zurawski Z, Betke KM, Yim YY, Hyde K, Rodriguez S, Alford S, Hamm HE (2012) Mol Pharmacol 82: 1136-49 A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Albanese A, Barnes MP, Bhatia KP, Fernandez-Alvarez E, Filippini G, Gasser T, Krauss JK, Newton A, Rektor I, Savoiardo M, Valls-Solè J (2006) Eur J Neurol 13: 433-44 Women Undergoing Third Line Overactive Bladder Treatment Demonstrate Elevated Thermal Temporal Summation. Reynolds WS, Kowalik C, Cohn J, Kaufman M, Wein A, Dmochowski R, Bruehl S (2018) J Urol 200: 856-861 Re: Treatment Outcomes and Resource Use of Patients With Neurogenic Detrusor Overactivity Receiving Botulinum Toxin A (BOTOX) Therapy in Germany. Penson DF (2011) J Urol 185: 1383-4 Structural analysis of botulinum neurotoxin type G receptor binding . Schmitt J, Karalewitz A, Benefield DA, Mushrush DJ, Pruitt RN, Spiller BW, Barbieri JT, Lacy DB (2010) Biochemistry 49: 5200-5 Five-year cost analysis of intra-detrusor injection of botulinum toxin type A and augmentation cystoplasty for refractory neurogenic detrusor overactivity. Padmanabhan P, Scarpero HM, Milam DF, Dmochowski RR, Penson DF (2011) World J Urol 29: 51-7 Recombinant expression and purification of the botulinum neurotoxin type A translocation domain. Lacy DB, Stevens RC (1997) Protein Expr Purif 11: 195-200 The Pathogenesis and Management of Achalasia: Current Status and Future Directions. Ates F, Vaezi MF (2015) Gut Liver 9: 449-63
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.